tradmap

ECOR electroCore, Inc.

$8.41 +17.95%

Data as of close

Healthcare · Electromedical & Electrotherapeutic Apparatus

electroCore, Inc. (ECOR) is a healthcare company in the Electromedical & Electrotherapeutic Apparatus industry, with a market capitalization of $78 million. Shares last traded at $8.41, 33.8% below their 52-week high. Over the past year the stock is up 65.2%. Net profit margin is -33.5%, below the peer median of -10.0%. Revenue grew 27.2% year over year.

Market Cap
$78M
Shares Out
9.2M
EPS (TTM)
-$1.39
P/E (TTM)*
—
P/S Ratio
2.04
P/B Ratio
—
Dividend / Share
—
Dividend Yield
—
52-Week High
$12.70
52-Week Low
$4.42
Volume (venue)
2,418
Avg Vol (3m, venue)
1,988.222

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
+1.75%
1M
-16.19%
3M
+20.14%
6M
+25.52%
YTD
+88.99%
1Y
+65.23%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
50.03
SMA (50)
$9.38
SMA (200)
$7.76
Price vs SMA50
-10.30%
Price vs SMA200
+8.42%
ATR (14)
$0.52

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$38M
Net Income
-$13M
Gross Margin
87.7%
Operating Margin
-33.1%
Net Margin
-33.5%
Return on Equity
—
Return on Assets
-73.6%
Current Ratio
1.34
Debt / Equity
—
Revenue Growth (YoY)
+27.2%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-09-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q3 2026 -$0.13 2026-11-04
Q2 2026 -$0.33 2026-08-06
Q1 2026 -$0.59 2026-05-06
Q4 2025 (derived) -$0.34 2026-03-19
FY 2025 -$1.65 2026-03-19
Q3 2025 -$0.40 2025-11-05

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Electromedical & Electrotherapeutic Apparatus peers

ECOR vs 14 industry peers (Electromedical & Electrotherapeutic Apparatus), by market cap. Data as of close

P/S vs peers
2.04 / 2.43 med
-16% discount
Net margin vs peers
-33.5% / -10.0% med
below median
1–14 of 14
MDTMedtronic$134.4B25.693.5813.9%+6.22%
LIVNLivanova Plc$5.2B26.473.4413.0%+17.67%
ITGRInteger Holdings Corp$4.3B41.522.365.7%+0.02%
AXGNAxogen, Inc.$3.1B—11.49-12.0%+3.67%
TMDXTransmedics Group, Inc.$2.5B16.623.7722.7%+7.85%
CNMDConmed Corp$1.6B34.011.163.4%+13.41%
CBLLCeribell, Inc.$1.1B—9.76-68.0%-3.50%
INMDInmode Ltd.$899M9.582.4325.3%+0.67%
CVCapsoVision, Inc$345M———+2.91%
ELMDElectromed, Inc.$234M20.703.1715.3%+4.25%
FOCLEDAP TMS SA$161M—2.28-41.5%-0.46%
VANIVivani Medical, Inc.$97M———+1.42%
STXSStereotaxis, Inc.$96M—3.18-74.2%+12.13%
NRXSNeuraxis, INC$86M———+2.94%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.